Aurobindo Pharma Ltd has received the tentative approval for the ANDA drug lamivudine and zidovudine tablets, 150 mg / 300 mg with combination. It is the first generic version of Glaxo SmithKline Plc's combination AIDS drug Combivir.

Lamivudine and zidovudine are in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing. This fixed-dose combination anti-retroviral drug is intended to be used with other antiretroviral agents for the treatment of HIV-1 infection.

This will also enable the company to participate in President's Emergency Plan for AIDS Relief (PEPFAR) programme, a company release said.